Stephen James - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 23.55  1.10  4.90%

Vice President Head of Drug Design and Development
Mr. Stephen James serves as Vice President, Head of Drug Design and Development at Swedish Orphan Biovitrum AB . He was employed by the Company since 2001. He previously held a number of management positions in Research and PreClinical Development in Pharmacia Upjohn, Pharmacia AB and Biovitrum AB. Prior to this, he served as University of Dundee Research Fellow, the United Kingdom. He holds a Doctorate of Philosophy degree in Biochemistry and Cell Biology from the University of Leeds, and a BS degree in Biochemistry and Microbiology from the University of St. Andrews.
Age: 49    Ph.D    
46 86 97 20 00

Management Efficiency

The company has return on total asset (ROA) of 11.67 % which means that it generated profit of $11.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 22.83 % meaning that it generated $22.83 on every $100 dollars invested by stockholders.
The company has accumulated 675.6 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.85 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Rafael AyalaEcopetrol S A
Adriana GutierrezEcopetrol S A
Juliana AlbanEcopetrol S A
JeanPhilippe CourtoisMicrosoft Corporation
Christopher CaposselaMicrosoft Corporation
Karen SantiagoBristol Myers Squibb Company
Fernan AriasEcopetrol S A
Emmanuel BlinBristol Myers Squibb Company
Hector AristizabalEcopetrol S A
Ann JudgeBristol Myers Squibb Company
Bradford SmithMicrosoft Corporation
Keith LorizioMicrosoft Corporation
Pedro NavarroEcopetrol S A
Louis SchmuklerBristol Myers Squibb Company
Pedro ManriqueEcopetrol S A
Margaret JohnsonMicrosoft Corporation
Felipe PardoEcopetrol S A
Nestor TrujilloEcopetrol S A
Eduardo UribeEcopetrol S A
Maria AlbanEcopetrol S A
John ElickerBristol Myers Squibb Company

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 816 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance Indicators

Did you try this?

Run Idea Optimizer Now

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Idea Optimizer

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Swedish Orphan and Bristol Myers Squibb. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.